TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  Benzinga

Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

Benzinga Logo Benzinga By Vandana Singh
Eli Lilly's Investigational Obesity Drug Shows Up To 20% Weight Loss In Phase 2 Study, Analyst Sees It As Emerging Cornerstone In Obesity Treatment

Eli Lilly reported promising Phase 2 trial results for eloralintide, an investigational obesity drug that demonstrated weight loss up to 20% in obese adults, with potential improvements in cardiometabolic risk factors.

Insights
NVDA   neutral

Mentioned as part of the AI chip ecosystem, but no specific analysis provided in the article


LLY   positive

Successful Phase 2 trial showing significant weight loss and potential for new obesity treatment, with analysts viewing the drug as an emerging cornerstone in obesity management